Literature DB >> 36033141

COVID-19 Pills - A Long Awaited Ally for Out-Patient Therapeutics.

Hariharan Regunath1.   

Abstract

Entities:  

Mesh:

Year:  2022        PMID: 36033141      PMCID: PMC9312460     

Source DB:  PubMed          Journal:  Mo Med        ISSN: 0026-6620


× No keyword cloud information.
  5 in total

1.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

Authors:  Dafydd R Owen; Charlotte M N Allerton; Annaliesa S Anderson; Lisa Aschenbrenner; Melissa Avery; Simon Berritt; Britton Boras; Rhonda D Cardin; Anthony Carlo; Karen J Coffman; Alyssa Dantonio; Li Di; Heather Eng; RoseAnn Ferre; Ketan S Gajiwala; Scott A Gibson; Samantha E Greasley; Brett L Hurst; Eugene P Kadar; Amit S Kalgutkar; Jack C Lee; Jisun Lee; Wei Liu; Stephen W Mason; Stephen Noell; Jonathan J Novak; R Scott Obach; Kevin Ogilvie; Nandini C Patel; Martin Pettersson; Devendra K Rai; Matthew R Reese; Matthew F Sammons; Jean G Sathish; Ravi Shankar P Singh; Claire M Steppan; Al E Stewart; Jamison B Tuttle; Lawrence Updyke; Patrick R Verhoest; Liuqing Wei; Qingyi Yang; Yuao Zhu
Journal:  Science       Date:  2021-11-02       Impact factor: 47.728

2.  Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

Authors:  Laura Vangeel; Winston Chiu; Steven De Jonghe; Piet Maes; Bram Slechten; Joren Raymenants; Emmanuel André; Pieter Leyssen; Johan Neyts; Dirk Jochmans
Journal:  Antiviral Res       Date:  2022-01-24       Impact factor: 5.970

3.  Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.

Authors:  Angélica Jayk Bernal; Monica M Gomes da Silva; Dany B Musungaie; Evgeniy Kovalchuk; Antonio Gonzalez; Virginia Delos Reyes; Alejandro Martín-Quirós; Yoseph Caraco; Angela Williams-Diaz; Michelle L Brown; Jiejun Du; Alison Pedley; Christopher Assaid; Julie Strizki; Jay A Grobler; Hala H Shamsuddin; Robert Tipping; Hong Wan; Amanda Paschke; Joan R Butterton; Matthew G Johnson; Carisa De Anda
Journal:  N Engl J Med       Date:  2021-12-16       Impact factor: 91.245

Review 4.  Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.

Authors:  George R Painter; Michael G Natchus; Oren Cohen; Wendy Holman; Wendy P Painter
Journal:  Curr Opin Virol       Date:  2021-06-18       Impact factor: 7.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.